Lantheus Holdings, Inc. · NASDAQ:LNTH
Lantheus — Investor Day (May 2022)
105 slides from Lantheus's investor day presentation, May 17, 2022
Slide 1: Lantheus 2022 Investor Day
Lantheus 2022 Investor Day May 17 | New York City Exhibit 99.1
Slide 2: Welcome & Opening Remarks
Welcome & Opening Remarks Mark Kinarney Senior Director, Investor Relations
Slide 3: Safe Harbor and Non-GAAP Financial Measures
Safe Harbor and Non-GAAP Financial Measures Cautionary Statement Regarding Forward-Looking Statements This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, that are subject to risks and uncertainties and are made pur
Slide 4: Today's Agenda
Today’s Agenda 9:00 AM Welcome and Opening Remarks Mark Kinarney, Senior Director, Investor Relations Vision and Strategy for the Next Phase of Growth Mary Anne Heino, President and CEO PYLARIFY – Prostate Cancer Franchise Overview Paul Blanchfield, Chief Commercial Officer Etienne Montagut, Chief B
Slide 5: Vision and Strategy for the Next Phase of Growth
Vision and Strategy for the Next Phase of Growth Mary Anne Heino President and CEO
Slide 6: Key Messages
Key Messages 65+ Years of Industry Leadership and Innovation from our diversified portfolio Proven Operational and Commercial Capabilities to capture significant growth opportunities and sustain them over the long-term Seasoned Leadership Team with deep expertise and strong execution track record of
Slide 7: Proven Management Team with Deep Industry Expertise
Proven Management Team with Deep Industry Expertise Mary Anne Heino President and Chief Executive Officer 2013 Previously: Janssen, Centocor, Inc, Angleini, Labopharm Robert Marshall Chief Financial Officer and Treasurer 2018 Previously: Zimmerbiomet, Brown and Williamson Tobacco Etienne Montagut Ch
Slide 8: Lantheus Holdings Snapshot
Lantheus Holdings Snapshot (NASDAQ: LNTH) (1) Positron Emission Tomography (2) DRG Echo Monthly Monitor (3) As of 5/10/22 KEY STATISTICS First and best-in-class PSMA PET1 imaging agent for prostate cancer #1 Ultrasound enhancing agent in the U.S. for almost 20 years2 Emerging therapeutic platform an
Slide 9: Where We Were, Where We Are, Where We Are Going
Where We Were, Where We Are, Where We Are Going (1) Pheochromocytoma and Paraganglioma A HISTORY OF INDUSTRY FIRSTS 2022 & ONWARD ACCELERATE POSITION DIVERSIFY 1956 Founded as New England Nuclear 1970 First commercially owned cyclotron begins producing radiopharmaceuticals 2021 First to launch a com
Slide 10: Competitive Advantages to Sustain Growth and Innovation
Competitive Advantages to Sustain Growth and Innovation Well Positioned to Find, Fight And Follow® Disease to Deliver Better Patient Outcomes with strong supply chain management DIVERSIFIED PRODUCT PORTFOLIO AND PIPELINE with expertise across the value chain RECOGNIZED LEADER IN RADIOISOTOPES with p
Slide 11: Our Strategy for Long-term Profitable Growth
Our Strategy for Long-term Profitable Growth Poised to Take Advantage of Renaissance in Radiopharmaceuticals DIVERSIFY our portfolio and optimize value through business development and strategic partnerships POSITION as category leader by enhancing operational and commercial excellence ACCELERATE gr
Slide 12: Experienced and Engaged Board of Directors
Experienced and Engaged Board of Directors SKILLS MATRIX Brian Markison Chairman of the Board CEO & Director of Osmotica Holdings, SCSp 2012 Mary Anne Heino President & CEO Lantheus Holdings 2015 Minnie Baylor-Henry President of B-Henry & Associates 2022 Dr. Gérard Ber Co-Founder & former COO, Advan
Slide 13: Key Takeaways
Key Takeaways 65+ Years of Industry Leadership and Innovation from our diversified portfolio Proven Operational and Commercial Capabilities to capture significant growth opportunities and sustain them over the long-term Seasoned Leadership Team with deep expertise and strong execution track record o
Slide 14: Prostate Cancer Franchise
Prostate Cancer Franchise Paul Blanchfield Chief Commercial Officer Etienne Montagut Chief Business Officer Aseem Anand VP of Digital Solutions
Slide 15: Key Messages
Key Messages (1) Addressable market based on current management estimates, internal data and observed market price. Significant Market Opportunity $1.1B+ U.S. PSMA PET TAM1 #1 PSMA PET Imaging Agent with First Mover Advantage strong PYLARIFY adoption-to-date Significant Long-Term Growth Potential th
Slide 16: Prostate Cancer 2nd Most Common Cancer in U.S. Men
Prostate Cancer (PCa) 2nd Most Common Cancer in U.S Men (1) American Cancer Society. Cancer Facts & Figures 2022. American Cancer Society; Atlanta, Ga. 2022; (2) Ceci & Fanti. PSMA-PET/CT imaging in prostate cancer: why and when. Clinical and Translational Imaging volume 7, pages 377–379 (2019).; (3
Slide 17: PSMA PET Imaging Can Enhance Therapeutic Decision Making
PSMA PET Imaging Can Enhance Therapeutic Decision Making PET imaging has the potential to improve disease localization, thus enhancing therapeutic decision-making1,2,6 PSMA PET can detect lesions between 4-8 mm, and therefore has a higher detection rate3,5 PSMA PET is also effective at lower PSAs3 I
Slide 18: $1.1B+ U.S. PSMA PET TAM
$1.1B+ U.S. PSMA PET TAM $92.8M in PYLARIFY Sales for 1Q’22 = ~34% Annualized Penetration Potential to Expand TAM with Expanding Therapeutic Utilization $1.1B+ U.S. TAM PYLARIFY #1 PSMA PET Imaging Agent U.S. PSMA PET Market U.S. PSMA PET Market Potential # of Annual Scans ~130K 52% ~90K 36% ~30K 12
Slide 19: PYLARIFY: First Commercially Available PSMA PET Imaging Agent
PYLARIFY | First Commercially Available PSMA PET Imaging Agent Game Changer to Find, Fight and Follow® This Important Disease PYLARIFY Indication: Indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: with suspecte
Slide 20: PYLARIFY: #1 PSMA PET Imaging Agent with Significant Momentum
PYLARIFY | #1 PSMA PET Imaging Agent with Significant Momentum (1) Revenue guidance as of April 29, 2022 <1% 99% 34% PYLARIFY Market Penetration Annualized Penetration First Commercially Available PSMA PET Imaging Agent $43M 2022 $385 – 420M PYLARIFY Revenue Guidance1 Annual Revenues Untapped Potent
Slide 21: PYLARIFY: Advantages to Sustain Market Leadership
PYLARIFY | Advantages to Sustain Market Leadership 2 SUPPLY & CAPACITY 3 CUSTOMER CONTRACTING & SERVICE 4 MARKET ACCESS 5 DEMAND GENERATION 6 TECHNOLOGY / AI 1 CLINICAL DIFFERENTIATION
Slide 22: PYLARIFY: Clinical Differentiation
PYLARIFY | Clinical Differentiation (1) 18F-PyL=18F-DCFPyL; 68Ga-PSMA=68Ga-PSMA-11.; (2) Dietlein F, et al. J Nuci Med.2017;58:947-952. 2. Dietlein F, et al. Mol Imaging Biol.2015; 17(3): 575-84; (3) 131 (64%) of evaluable patients had a change in intended management after PYLARIFY PET/CT; (4) 103 (
Slide 23: PYLARIFY: Batch Manufacturing Process
PYLARIFY | Batch Manufacturing Process Optimal for Patient Treatment Logistics Scalable Manufacturing Process to Meet Patient Needs F 18 is produced on a cyclotron Best-in-class technology Robust quality control and testing Drawn into patient-ready doses PYLARIFY is manufactured and formulated in a
Slide 24: PYLARIFY: PMF Model Provides Significant Capacity
PYLARIFY | PMF1 Model Provides Significant Capacity (1) PMF = PET Manufacturing Facility; (2) Source: IMV 2022 PET Imaging Market Summary Report Capacity to Produce 150-200K PYLARIFY Doses in 2022 PYLARIFY Supply Advantages Leverages Sizeable U.S. PMF Network U.S. cyclotron network already supports
Slide 25: PYLARIFY: Activated Network Serves 80%+ of U.S. Population
PYLARIFY | Activated Network Serves 80%+ of U.S. Population1 (1): As of 5/17/22 Enabling Access for Customers and Their Patients Active PMFs
Slide 26: PYLARIFY: Future Activations Enhance Redundancy and Reach
PYLARIFY | Future Activations1 Enhance Redundancy and Reach Enabling PYLARIFY to Remain the #1 PSMA PET Imaging Agent Active PMFs Planned Future PMFs (1): As of 5/17/22
Slide 27: PYLARIFY: First Mover Advantage and Delivery Effectiveness
PYLARIFY | First Mover Advantage and Delivery Effectiveness (1) Internal Lantheus estimate of prioritized accounts PYLARIFY Contracts with Vast Majority of Targeted Accounts 4Q21 1Q22 PYLARIFY Manufacturing Effectiveness % Dose On-Time-In-Full PYLARIFY Customer Contracting % of Targeted Accounts Con
Slide 28: PYLARIFY: 90%+ of Prostate Cancer Lives Covered
PYLARIFY | 90%+ of Prostate Cancer Lives Covered PYLARIFY Market Access Progress PROSTATE CANCER PAYERS Estimated Distribution Achieving Best-in-Class Coverage Levels for PYLARIFY ~35% ~35% ~25% ~ Traditional Medicare Medicare Advantage Commercial Other Coverage 90%+ of covered lives have access to
Slide 29: PYLARIFY: Largest Dedicated PSMA PET Commercial Team
PYLARIFY | Largest Dedicated PSMA PET Imaging Commercial Team Educating on Availability and Differentiation of PYLARIFY PYLARIFY Launch Resourcing SALES & MARKETING Largest 100% dedicated U.S. PSMA PET sales team Calls on PET Imaging Sites & Referring HCPs Two-thirds with deep urology experience One
Slide 30: PYLARIFY: ~700 Unique Customers Have Ordered Since Launch
PYLARIFY | ~700 Unique Customers Have Ordered Since Launch *Note not all sites enable us to provide access information Availability* Broad Availability and Adoption across the U.S.
Slide 31: PYLARIFY: Robust Customer Adoption
PYLARIFY | Robust Customer Adoption Quarterly Customers Ordering Doses by Customer Type % of Total Repeat Ordering Patterns % of Total Customers as of 1Q22 Strong Adoption with Significant Breadth and Depth 95% Ordered 2+ doses 53% Ordered 20+ doses Imaging Center ~150 ~375 <10 ~700 Once sites order
Slide 32: PYLARIFY: Opportunity for Sustainable Franchise Growth
PYLARIFY | Opportunity for Sustainable Franchise Growth Strong Advantages to Maximize Long-term Potential PARTNERSHIPS 3 MARKET EXPANSION 2 CUSTOMER RETENTION 1
Slide 33: PYLARIFY: Customer Retention
PYLARIFY | Customer Retention Sustainable Post Pass-Through PYLARIFY Franchise Expected to Remain Robust Site of Care / Payer Mix Majority of patients are NOT subject to traditional pass-through payment status: ~70% of current business is hospital based ~30% of patient mix is Traditional Medicare Me
Slide 34: PYLARIFY: Market Expansion Opportunities
Metastatic: Intermediate Favorable Patients Exploring other geographies Opportunity to Expand on Current Leadership Partnered for Geographic Expansion Europe UK Planned Geographic Expansion Potential TAM Expansion via Expanded PSMA Tx2 Usage 1st Line mCRPC or Metastatic Hormone-Sensitive Prostate Ca
Slide 35: PYLARIFY: Use in PSMA Therapeutic Trials
Broad use across multiple therapeutic modalities in most late-stage trials reinforces PYLARIFY’s role to Find, Fight and Follow® disease PYLARIFY | Use in PSMA Therapeutic Trials Source: Citeline Pharmaprojects search of PSMA targeted therapeutics in the U.S. Strategic partnerships with pharmaceutic
Slide 36: PYLARIFY AI: Mining Rich Imaging Data for Clinical Value
PYLARIFY AI | Mining Rich Imaging Data for Clinical Value AI technology mines and contextualizes rich PYLARIFY imaging data to enhance clinical decision making: Enhancing Clinical Decision Making to Deliver Better Patient Outcomes Increase throughput of image analysis Enhance reproducibility and rel
Slide 37: PYLARIFY AI Demo
PYLARIFY AI DEMO
Slide 38: Standardized Objective Analysis for Better Patient Management
Transitioning from Anecdotal and Subjective Reporting to a Standardized Objective Analysis for Better Patient Management Current Typical Nuclear Medicine Report Objective Standardized PYLARIFY AI Reporting PSMA Score – 165 Patient Study data Patient name (Gender) Demo-1-002 (M) Study date 29 Sep, 20
Slide 39: Key Takeaways
Key Takeaways (1) Addressable market based on current management estimates, internal data and observed market price. Significant Market Opportunity $1.1B+ U.S. PSMA PET imaging TAM1 #1 PSMA PET Imaging Agent with First Mover Advantage strong PYLARIFY adoption-to-date Significant Long-Term Growth Pot
Slide 40: PYLARIFY KOL Panel
PYLARIFY KOL Panel Moderator: Bela Denes, M.D. VP, Medical Affairs E. David Crawford, M.D. Professor of Urology University of California, San Diego Michael J. Morris, M.D. Section Head, Prostate Cancer, Memorial Sloan Kettering Cancer Center
Slide 41: Q&A
G Lantheus /~ Holdings Q&A
Slide 42: Break
Lantheus /~ Holdings Break ~10 Minutes
Slide 43: Microbubble Franchise
Paul Blanchfield Chief Commercial Officer Microbubble Franchise Etienne Montagut Chief Business Officer
Slide 44: Key Messages
Key Messages (1) Addressable market based on current management estimates, internal data and observed market price; (2) Data on file, Lantheus Medical Imaging, Inc. Opportunity U.S. Ultrasound Enhancing Agent (UEA) TAM is $600M+1 Leading Market Share with Defensible Position DEFINITY is the #1 UEA i
Slide 45: Heart Disease #1 Cause of Death in the U.S.
Heart Disease #1 Cause of Death in the U.S.1 | 100M+ Impacted American Heart Association: 2022 Heart Disease and Stroke Statistics Update Fact Sheet: (1) 2022; (2) 2019; (3) 2017 & 2018 Lantheus | Find, Fight and Follow® Serious Medical Conditions Cardiovascular disease (CVD) accounts for 12% of tot
Slide 46: High-resolution Echocardiograms Can Help Improve Patient Management
High-resolution Echocardiograms Can Help Improve Patient Management1 LEFT VENTRICULAR THROMBUS The Challenges of Non-diagnostic Echoes Even with advancements in echocardiography, imaging can be suboptimal2, which may lead to1: Inadequate treatment plans Unnecessary additional testing Increased hospi
Slide 47: $600M+ U.S. Ultrasound Enhancing Agent TAM
$600M+ U.S. Ultrasound Enhancing Agent TAM ~$280M Existing Market | DEFINITY 80%+ Market Share1 U.S. Echo Market # of Annual Scans 25-32M Echoes performed in the U.S. annually2 20-30% or 5-10M are considered suboptimal3 U.S. Ultrasound Enhancing Agent Market ($M) $600M+ U.S. TAM DEFINITY #1 UEA in t
Slide 48: DEFINITY: Market Leading U.S. Ultrasound Enhancing Agent
DEFINITY | Market Leading U.S. Ultrasound Enhancing Agent WORLDWIDE VIALS DEFINITY Indication: for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border Sustained Market Leadership Product Por
Slide 49: DEFINITY: Advantages to Sustain Market Leadership
DEFINITY | Advantages to Sustain Market Leadership Sustainable Product/Clinical Differentiation Commercial & Distribution Model HCP Education & Demand Generation Supporting Data & Publications Robust Patent Portfolio 1 2 3 4 5
Slide 50: DEFINITY: Sustainable Clinical Differentiation
DEFINITY | Sustainable Clinical Differentiation The only ultrasound enhancing agent with multiple dosing and administration options1,2,3 Improves cardiac diagnosis and changes patient management4 Activated using novel activation devices designed to enhance optimum performance & safety in imaging1,5
Slide 51: DEFINITY: Differentiated Commercial and Direct Distribution Model
DEFINITY | Differentiated Commercial Model and Direct Distribution Model Commercial and Distribution Models Support Sustainability Largest UEA sales team with significant experience – average tenure 10+ years Direct contracts with 3,000+ customers Lantheus distributes DEFINITY in the U.S. to end-cus
Slide 52: DEFINITY: Supporting Education and Driving Demand
DEFINITY | Supporting Education and Driving Demand Customer Support and Insights Support Sustainability Significant educational investment Echo Application Specialists Peer-to-Peer programs Echo Quality Improvement Program Educational webinars and case studies EDUCATIONAL PROGRAMS More than 18 milli
Slide 53: DEFINITY: Most Chosen, Studied, Trusted UEA in the U.S.
DEFINITY | Most Chosen, Studied, Trusted UEA in the U.S. (1) Sperling D, et al. International Journal of Cardiology. 2021;11.040 (2) Main ML, et al. Am J Cardiol. 2021;00:1-6 (3) K. Charlotte Lee, et al. Journal of ASE. 2021; 34: 12 Influencing the Science and Increasing Community Engagement RECENT
Slide 54: DEFINITY: Robust Patent Portfolio and Sustainable Advantages
DEFINITY | Robust Patent Portfolio and Sustainable Advantages DEFINITY – 5 Orange-Book listed method of use patents, as well as additional manufacturing patents that are not Orange-Book listed DEFINITY RT – 6 Orange-Book listed patents including a composition of matter patent and method of use paten
Slide 55: DEFINITY: Dual Source Manufacturing Approved in 1Q22
DEFINITY | Dual Source Manufacturing Approved in 1Q22 Continuously Improving Operational and Commercial Capabilities GENESIS: On-campus DEFINITY manufacturing facility approved IMPROVES SUPPLY CHAIN EFFICIENCY MARGIN EXPANSION OPPORTUNITY Redundant, flexible internal manufacturing capability Enhance
Slide 56: DEFINITY: Partnerships for Microbubble Therapy Applications
GLIOBLASTOMA RETINAL VEIN OCCLUSION GLIOBLASTOMA XEROSTOMIA DEFINITY | Partnerships for Microbubble Therapy Applications Gene therapy Chemotherapy Other targeted therapies Direct action, e.g., Sonothrombolysis Strategic Partnerships Open New Market Opportunities and Optionality Aims of Using Microbu
Slide 57: Key Takeaways
Key Takeaways (1) Addressable market based on current management estimates, internal data and observed market price; (2) Data on file, Lantheus Medical Imaging, Inc. Opportunity U.S. Ultrasound Enhancing Agent (UEA) TAM is $600M+1 Leading Market Share with Defensible Position DEFINITY is the #1 UEA
Slide 58: Uniquely Positioned for Radiopharmaceutical Renaissance
Uniquely Positioned for Radiopharmaceutical Renaissance Jean-Claude Provost, M.D. Interim Chief Medical Officer Moderator: Bela Denes, M.D. VP, Medical Affairs
Slide 59: Renaissance in Radiopharmaceuticals
Renaissance in Radiopharmaceuticals Since inception, Lantheus has been leveraging the power of targeted radioisotopes Mould, Richard Francis (1993). A century of x-rays and radioactivity in medicine: with emphasis on photographic records of the early years. CRC Press. ISBN 9780750302241.; Fornell, D
Slide 60: Improving Performance Characteristics with Novel Radiopharmaceuticals
Improving Performance Characteristics with Novel Radiopharmaceuticals Disease Targeted Solutions for Personalized Patient Treatment Increasing Target Specificity (example with prostate cancer) Use of Better Fit-for-Purpose Isotopes Novel isotopes Combinations or sequences (a, b therapies) Combinatio
Slide 61: Diverse Radiopharmaceutical Technology Applications Broaden Opportunity
Diverse Radiopharmaceutical Technology Applications Broaden Opportunity IMAGING THERAPY + α and β Therapy Therapeutic radioisotopes can deliver a cancer-killing payload precisely to sites that express the target throughout the body, as identified through imaging Radioisotopes delivering either alpha
Slide 62: Lantheus Has the Right Experience and Know How to Capture the Opportunity
Lantheus Has the Right Experience and Know How to Capture the Opportunity * In development # In development through partners Radiopharmaceutical Expertise Acquired Over 65+ Years Differentiates Lantheus in This Renaissance Manufacturing and Supply Chain Capabilities Dealing with complex radiopharmac
Slide 63: Executing the Growth Strategy
Etienne Montagut Chief Business Officer Executing the Growth Strategy
Slide 64: Key Messages
Key Messages Early Access to Innovation through a multi-channel approach Optimization of Assets with partnerships and AI Enable Multiple Strategic Opportunities through business development and R&D
Slide 65: Three Engines for Fostering New Growth Opportunities
Three Engines for Fostering New Growth Opportunities Multiple Shots on Goal to Support Short and Long-term Growth PHARMA SERVICES & DIGITAL SOLUTIONS Source new innovations to feed pipeline Fund and de-risk development Nurture potential business development targets INCUBATE THERAPEUTIC COMMERCIAL PL
Slide 66: Business Development: Search Criteria
Search Criteria Late or commercial-stage assets High growth, high margin assets Focus on strengthening our three categories Focusing on Expanding Product Portfolio FIND FOLLOW Pharma Partnerships Digital Solutions FIGHT Business Development | Building and Expanding from Progenics Acquisition
Slide 67: Pharma Services and Digital to Accelerate Innovation
Pharma Services and Digital to Accelerate Innovation Multiple Partnering Platforms Working Synergistically to Drive Growth and Optionality aBSI: Automated Bone Scan Index; References: (1) DRG Prostate Cancer Disease Landscape and Forecast (2) GlobalData and TrialTrove trial data, management analysis
Slide 68: Filling and Incubating Early-Stage Pipeline with PD-L1 Imaging Agent
Illustration of Filling and Incubating Early-Stage Pipeline with PD-L1 Imaging Agent $40B Immune checkpoint market1 70% Non responders2 ~17% Grade 3-5 severe adverse events3 $150K Immune checkpoint average annual cost of therapy1 Unmet Medical Need Despite substantial benefits of checkpoint therapie
Slide 69: Snapshot of Strategic Partnerships Across Portfolio
Snapshot of Strategic Partnerships Across Portfolio RELISTOR Microbubble Oncology 1404 aBSI and aPROMISE Piflufolastat F 18 New Biomarkers Flurpiridaz F 18
Slide 70: Advancing our Pipeline with Innovative Platforms
DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 APPROVED Advancing our Pipeline with Innovative Platforms Maximizing Franchise Value and Bringing New Options to Pipeline Microbubble Partnerships Radiopharmaceutical Diagnostics Radiotherapeutics NTI-1309 – FAP Imaging LMI 1195 – Neuroendocrine Tumor Im
Slide 71: Key Takeaways
Key Takeaways Early Access to Innovation through a multi-channel approach Optimization of Assets with partnerships and AI Enable Multiple Strategic Opportunities through business development and R&D
Slide 72: Financial Highlights
Financial Highlights Bob Marshall CFO and Treasurer
Slide 73: Key Messages
Key Messages Continuing to Execute for long-term profitable growth after an exciting and productive 2021 Enabling Sustained Financial Outperformance Revenue growth Margin expansion FCF generation Fueling Our Capital Allocation Priorities through a flexible balance sheet and strong cash generation to
Slide 74: Executing to Deliver Profitable Growth
Executing to Deliver Profitable Growth Diversified and Growing Revenue Base Enabled Profitability While Investing for the Future +37.3% CAGR Exceptional talent, expertise, and capabilities Growth in DEFINITY market leadership and revenues Capturing Progenics synergies and investing in PYLARIFY growt
Slide 75: Profitability and Disciplined CapEx Driving Positive FCF Trends
Profitability and Disciplined CapEx Driving Positive FCF Trends Delivered positive FCF despite Progenics acquisition and COVID-19 impacts during 2020 PYLARIFY and DEFINITY driving recent success and signaling an inflection point for FCF growth Record 2022 estimate sets foundation for sustainable FCF
Slide 76: Balance Sheet and Capital Structure Allow for Improved Access to Capital
Balance Sheet and Capital Structure Allow for Improved Access to Capital Summary Balance Sheet ($M) March 31, 2022 March 31, 2022 Cash and Cash Equivalents $105.4 Total Assets $933.2 Long-term Debt $159.4 Total Liabilities $417.3 Total Stockholders’ Equity $515.9 Total Liabilities and Stockholders’
Slide 77: Capital Allocation Philosophy Drives Sustainable Growth
Capital Allocation Philosophy Drives Sustainable Growth $694M deployed over last 3 years through Dec. 31, 2021 Focused on Delivering Strong Compounding Returns on Capital over the Long-term Redeploy capital into portfolio, pipeline, and strategic partnership opportunities Tech and data investments t
Slide 78: Disciplined Strategic and Financial Approach to Inorganic Growth
Disciplined Strategic and Financial Approach to Inorganic Growth Clear and Proven M&A Playbook Financial criteria Revenue streams that sustain long-term double-digit growth Maximizing OpEx synergy opportunities Margin accretive, notably Gross Profit and EBITDA margins Strong return profile Reasonabl
Slide 79: Demonstrated Execution: Progenics
Demonstrated Execution | Progenics FINANCIAL PRIORITIES WHAT WE SAID WHAT WE DID Revenue streams that sustain long-term double-digit growth Combined revenue of $595M by 2022 On Track Maximize OpEx synergies ~$15 – $20M run-rate cost savings by 2022 Realized $26M in run-rate savings by YE 2021 Capita
Slide 80: Long-term Financial Targets
(1) FCF = Free Cash Flow = Operating Cash Flow less Capital Expenditures; 2022-2025 cumulative estimate Long-term Financial Targets Investing and Optimizing for Profitable Growth Delivering levered P&L Disciplined investment to support growth and efficiencies EBITDA Margin 45%+ Favorable volume and
Slide 81: Key Takeaways
Key Takeaways Continuing to Execute for long-term profitable growth after an exciting and productive 2021 Enabling Sustained Financial Outperformance Revenue growth Margin expansion FCF generation Fueling Our Capital Allocation Priorities through a flexible balance sheet and strong cash generation t
Slide 82: Closing Remarks
Closing Remarks Mary Anne Heino President and CEO
Slide 83: Proven Management Team with Deep Industry Expertise
Proven Management Team with Deep Industry Expertise Mary Anne Heino President and Chief Executive Officer 2013 Previously: Janssen, Centocor, Inc, Angleini, Labopharm Robert Marshall Chief Financial Officer and Treasurer 2018 Previously: Zimmerbiomet, Brown and Williamson Tobacco Etienne Montagut Ch
Slide 84: Q&A Session
G Lantheus /~ Holdings Q&A Session
Slide 85: Appendix
G Lantheus /~ Holdings Appendix
Slide 86: GAAP to Non-GAAP Reconciliation Tables
GAAP to Non-GAAP Reconciliation Tables On a forward-looking basis, the Company does not provide GAAP income per common share guidance or a reconciliation of adjusted fully diluted EPS to GAAP income per common share because the Company is unable to predict with reasonable certainty business developm
Slide 87: Reconciliation of Free Cash Flow
Reconciliation of Free Cash Flow On a forward-looking basis, the Company does not provide GAAP net cash provided by operating activities guidance or a reconciliation of free cash flow to GAAP net cash provided by operating activities because the Company is unable to predict with reasonable certainty
Slide 88: GAAP to Non-GAAP Reconciliation Tables
GAAP to Non-GAAP Reconciliation Tables
Slide 89: GAAP to Non-GAAP Reconciliation Tables
GAAP to Non-GAAP Reconciliation Tables
Slide 90: GAAP to Non-GAAP Reconciliation Tables
GAAP to Non-GAAP Reconciliation Tables
Slide 91: GAAP to Non-GAAP Reconciliation Tables
GAAP to Non-GAAP Reconciliation Tables
Slide 92: As Adjusted Condensed Consolidated Statement of Operations – 1Q 2022
As Adjusted Condensed Consolidated Statement of Operations – 1Q 2022
Slide 93: Condensed Consolidated Statement of Operations – 1Q 2022
Condensed Consolidated Statement of Operations – 1Q 2022
Slide 94: GAAP to Non-GAAP Reconciliation Tables
GAAP to Non-GAAP Reconciliation Tables
Slide 95: Presenter Bios
G Lantheus /~ Holdings Presenter Bios
Slide 96: Mary Anne Heino
Mary Anne Heino brings to Lantheus 30 years of diverse pharmaceutical industry experience. Joining Lantheus in April 2013 as Chief Commercial Officer, Ms. Heino was promoted to Chief Operating Officer in March 2015 and to President and Chief Executive Officer in August 2015. Prior to joining Lantheu
Slide 97: Robert J. Marshall Jr.
Robert J. Marshall Jr. joined Lantheus as Chief Financial Officer and Treasurer in September 2018. Mr. Marshall brings to the Company more than 30 years of finance experience, including in M&A, capital markets and investor relations. Prior to joining Lantheus, Mr. Marshall spent 16 years with Zimmer
Slide 98: Paul Blanchfield
Paul Blanchfield serves as our Chief Commercial Officer, having joined Lantheus in January 2020. Prior to Lantheus, Mr. Blanchfield worked at Takeda Pharmaceutical Co. where he served as the Head of the U.S. Immunology Business Unit and managed a multi-billion-dollar P&L covering multiple rare disea
Slide 99: Jean-Claude Provost, MD
Jean-Claude Provost, MD joined Lantheus as Interim Chief Medical Officer in April 2022. Dr Provost brings to the Company more than 30 years of experience in international development of therapeutic drugs and diagnostic agents, including radiopharmaceuticals and contrast media agents. During his care
Slide 100: Etienne Montagut
Etienne Montagut joined Lantheus as Senior Vice President, Corporate Development in September 2018. Mr. Montagut brings to the Company more than 20 years of commercial, portfolio management and business development & licensing experience. Prior to joining Lantheus, Mr. Montagut spent the last six ye
Slide 101: Aseem Anand, PhD
Aseem Anand, PhD. is the Vice President of Digital Imaging Biomarker at Lantheus. Since 2018, Dr. Anand has been leading EXINI Diagnostics AB, in Sweden, a wholly owned subsidiary of Lantheus Holdings. Under his leadership, EXINI has developed and commercially launched novel deep learning algorithms
Slide 102: Bela Denes, M.D.
Dr. Bela Denes (Vice President, Medical Affairs) is a board-certified urologist who practiced for 25 years and subsequently has had a distinguished industry career. Prior to joining Lantheus, Dr. Denes was the Global Medical Affairs Lead at Amgen, responsible for overseeing the medical plans, launch
Slide 103: Mark Kinarney
After graduate school, Mark spent nine years in equity research at Merrill Lynch, Morgan Stanley and UBS. After several years away, Mark returned to the sell side to work in corporate access at Credit Suisse for four years. From 2016-2018, Mark worked on the Investor Relations team at Foster City-ba
Slide 104: Michael Morris, M.D.
Dr. Morris is a prostate cancer specialist, clinical investigator, professor, and the Section Head of Prostate Cancer of the Genitourinary Oncology Service at Memorial Sloan-Kettering Cancer Center. He earned his medical degree from the Mount Sinai School of Medicine in New York and performed his in
Slide 105: E. David Crawford, M.D.
Dr. Crawford is a board-certified urologist who has devoted his career in medicine to educating the public about men's health issues and finding effective techniques and procedures to address prostate cancer, the most common malignancy affecting men in the United States. He is an internationally rec